351 East Evelyn Avenue
United States - Map
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
|VIVUS Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 9; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Seth H. Z. Fischer ,
Chief Exec. Officer, Chief Commercial Officer and Director
|Mr. John L. Slebir Esq.,
Sr. VP of Bus. Devel., Gen. Counsel and Sec.
|Dr. Wesley W. Day Ph.D.,
VP of Clinical Devel.
|Dr. Santosh T. Varghese M.D.,
VP of Medical & Regulatory Affairs, Pharmacovigilance and QA
|Mr. Mark K. Oki CPA,
Chief Financial Officer and Chief Accounting Officer
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|